Arimoclomol Molecular Chaperone for Restoring GBA Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for GBA-associated alpha-synucleinopathies, such as Parkinson's disease and related disorders, do not effectively address the underlying issue of reduced glucocerebrosidase (GBA) enzyme levels and activity, which are linked to these conditions.
Innovation Solution
Arimoclomol, a heat shock protein amplifier, increases GBA levels and activity in both homozygous and heterozygous GBA mutation carriers, including those clinically unaffected by Gaucher's disease, thereby enhancing GBA enzyme function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for GBA-associated alpha-synucleinopathies, then current standard therapy is maintained, but the underlying issue of reduced GBA enzyme levels and activity is not effectively addressed
Solution Approach 1:
Arimoclomol acts as a molecular chaperone that mediates between the mutated GBA gene product and proper enzyme folding/function. The compound binds to misfolded GBA proteins and facilitates their correct conformation, thereby restoring enzyme activity without requiring gene replacement or complex therapeutic interventions
Solution Approach 2:
The invention changes the physicochemical parameters of the GBA enzyme by introducing arimoclomol molecules that alter the protein's conformational state. This small molecule modifies the enzyme's folding kinetics and stability parameters, transforming inactive misfolded proteins into active functional enzymes
2Reliability
If arimoclomol is used to increase GBA levels and activity, then enzyme function is enhanced, but the complexity of the pharmacological approach increases
Solution Approach 1:
Arimoclomol enables the GBA enzyme to serve itself by facilitating proper folding and stabilization of the protein. The molecular chaperone allows the endogenous enzyme to achieve its functional state without requiring external gene therapy or enzyme replacement, leveraging the cell's own protein synthesis and folding machinery
3Reliability
If arimoclomol is administered to increase GBA activity in mutation carriers, then therapeutic benefit is achieved, but the need for long-term pharmacological treatment arises
Solution Approach 1:
The invention establishes continuous therapeutic action through chronic arimoclomol administration that maintains elevated GBA enzyme activity levels. The molecular chaperone provides sustained stabilization of the enzyme, requiring ongoing treatment to maintain the beneficial effects on protein folding and enzyme function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Arimoclomol significantly increases GBA activity in patients with GBA mutations, offering potential therapeutic benefits for GBA-associated disorders like Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy by restoring enzyme function and reducing alpha-synuclein aggregation.
Implementation Method 1
Arimoclomol is a heat shock protein amplifier currently under evaluation in the treatment of paediatric lysosomal storage disorders and amyotrophic lateral sclerosis (ALS). The present inventors have now found that arimoclomol increases GBA levels and increases GBA activity
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders.